5AM Ventures is a leading venture capital firm that specializes in building next-generation life science companies. The firm focuses on early-stage investing in the biopharmaceutical, medical technology, and health care sectors.

5AM was founded in 2002 and pursues investments in advanced life science innovations, and seeks to be diversified across the biopharmaceutical therapeutics, and platform technologies.  Within each sector, 5AM invests across multiple therapeutic areas and modalities and evaluates opportunities based on innovative platform technologies, corporate spin-offs and products with shorter development cycles.

Content 5AM shares on this platform is not, and may not be relied on, in any manner, as legal, tax, investment, accounting or other advice or as an offer to sell or a solicitation of an offer to buy an interest in any private fund, special purpose or other investment vehicle sponsored by 5AM Ventures. Content 5AM shares on this platform is not an investment recommendation.

For a full list of all 5AM portfolio companies, please visit: https://5amventures.com/portfolio/

Homology Medicines

IDEAYA Biosciences

Vor Biopharma

VBI Vaccines

Impel NeuroPharma

scPharmaceuticals

Cabaletta Bio

Humanigen

CinCor Pharma

Crinetics Pharmaceuticals

Disc Medicine

Akouos

Ambrx

Arvinas

Audentes Therapeutics

Entrada Therapeutics

Pear Therapeutics

Precision NanoSystem

Pulmatrix

Purigen Biosystems

Rallybio

5AM Ventures

We are pleased to announce that we’ve received FDA Fast Track Designation for AlloNK® (also known as AB-101) for the treatment of lupus nephritis in combination with rituximab or obinutuzumab. Artiva previously received FDA clearance of an Investigational New Drug (IND) application for AlloNK in combination with rituximab in LN, marking the first IND clearance of an allogeneic, off-the-shelf NK cell therapy in autoimmune disease. 

https://lnkd.in/gXGDPAmE 

#AlloNK #NKcell #NKcells #clinicaltrials #clinicaltrial #autoimmunedisease #lupus #autoimmunity

We are thrilled that Deborah Palestrant has joined as a board member of Life Science Cares Boston!

Significant research exploring the potential of NodThera’s brain-penetrant #NLRP3 #inflammasome inhibitors to reverse diet-induced #obesity and #inflammation has been published in the Journal of Pharmacology and Experimental Therapeutics. 

The paper, entitled ‘Reversal of high fat diet-induced obesity, systemic inflammation and astrogliosis by the NLRP3 inflammasome inhibitors NT-0249 and NT-0796’ demonstrates for the first time the ability of NT-0796 and NT-0249 to not only induce statistically significant reductions in body fat in an animal model, but also reduce disease-relevant inflammatory biomarkers, suggesting the potential of NLRP3 inhibitors to further reduce cardiovascular risk in obese populations. 

To learn more visit https://bit.ly/3welbXR

Today we are excited to emerge from stealth with a $135 million Series A financing. Westlake Village BioPartners® incubated the company and led the Series A financing, with 5AM Ventures and Foresite Capital as co-leads and with participation from Corner Ventures. Latigo is focused on developing non-opioid novel pain medicines against genetically validated targets. Read the full press release here:

https://lnkd.in/g6BS44pT

#biotech #genetics #opioid

Congratulations to the Latigo Biotherapeutics, Inc. team!

🎙️Thrilled to share my recent podcast experience on NextGen VC by LaunchBio Inc. with hosts Michael Hostetler and Jennifer Fang from Wilson Sonsini! It was an incredible opportunity to reflect on my journey and delve into the exciting world of biotech. Huge thanks to Mike and Jen for the engaging conversation and to the amazing team at 5AM Ventures for their support. Grateful for the chance to share insights and learnings, and looking forward to more enriching discussions ahead!

Today we announced receipt of an ~$11 million milestone payment from Mundipharma following European approval of our invasive candidiasis drug in adult patients. Read the press release: https://brnw.ch/21wGTHJ

We are pleased to welcome Dr. Thomas Jaecklin to NodThera as Chief Medical Officer. With more than 20 years of experience across global large #pharma, #biotech and academic medicine, Thomas is an accomplished late-stage #DrugDevelopment leader with deep expertise across multiple therapy areas, including neuroscience and #inflammation. 

Prior to joining NodThera, Thomas was Vice President, Global Program Head of the Small Molecule Portfolio at Galapagos, where his strategic guidance led to multiple successful regulatory submissions and approvals. He also served as Senior Vice President, Head of #ClinicalDevelopment at Mirum Pharmaceuticals, leading the spin-off of two assets to successful registration and assisting in its $120 million Series A Financing and subsequent IPO. 

To find out more about Thomas’s appointment and experience: https://lnkd.in/e8YkYBh9

Welcome to NodThera Thomas!

#Appointment #NewHire #NLRP3 #Inflammasome #NeuroInflammation

#NEWS: Arvinas and Pfizer’s investigational treatment receives FDA Fast Track designation for patients with ER+/HER2- metastatic #breastcancer  
https://rb.gy/4k3n43

Today our treatment for adults with invasive candidiasis has been approved by the United Kingdom MHRA. Read here for more information on this milestone: https://brnw.ch/21wGuRc

COM:5AMVENTURES

5AM Ventures

Analysis Not Available